Premium
Deregulation of miR‐92a expression is implicated in hepatocellular carcinoma development
Author(s) -
Shigoka Masatoshi,
Tsuchida Akihiko,
Matsudo Takaaki,
Nagakawa Yuichi,
Saito Hitoshi,
Suzuki Yoshiaki,
Aoki Tatsuya,
Murakami Yoshiki,
Toyoda Hidenori,
Kumada Takashi,
Bartenschlager Ralf,
Kato Nobuyuki,
Ikeda Masanori,
Takashina Tomoki,
Tanaka Masami,
Suzuki Rieko,
Oikawa Kosuke,
Takanashi Masakatsu,
Kuroda Masahiko
Publication year - 2010
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2010.02526.x
Subject(s) - antagomir , microrna , hepatocellular carcinoma , cancer research , biology , gene , medicine , pathology , oncology , genetics
MicroRNAs (miRNAs) belong to a class of the endogenously expressed non‐coding small RNAs which primarily function as gene regulators. Growing evidence suggests that miRNAs have a significant role in tumor development and may constitute robust biomarkers for cancer diagnosis and prognosis. The miR‐17‐92 cluster especially is markedly overexpressed in several cancers, and is associated with the cancer development and progression. In this study, we have demonstrated that miR‐92a is highly expressed in hepatocellular carcinoma (HCC). In addition, the proliferation of HCC‐derived cell lines was enhanced by miR‐92a and inhibited by the anti‐miR‐92a antagomir. On the other hand, we have found that the relative amount of miR‐92a in the plasmas from HCC patients is decreased compared with that from the healthy donors. Interestingly, the amount of miR‐92a was elevated after surgical treatment. Thus, although the physiological significance of the decrease of miR‐92a in plasma is still unknown, deregulation of miR‐92 expression in cells and plasma should be implicated in the development of HCC.